Clinical Trial Update: XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing XP13512 (GSK1838262) to placebo in patients with Restless Legs Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• XP13512 (GSK1838262)

Snippet

Sponsor: XenoPort, Inc. | Conditions: Restless Legs Syndrome | Phase 3 | Status: COMPLETED